Longeveron Inc. (LGVN) Dividend History

Longeveron Inc. (LGVN) is a biotechnology company focused on developing regenerative medicine therapies, particularly using cellular and molecular approaches to address aging-related diseases and chronic conditions. The company emphasizes treatments derived from proprietary mesenchymal stem cell technology and other biologics to promote tissue repair and restore health.

1951 Nw 7th Avenue, Miami, FL, 33136
Phone: 305-302-7158
Website: https://www.longeveron.com

Dividend History

Longeveron Inc. currently does not pay dividends

Company News

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting

Longeveron presented positive long-term survival data for its Lomecel-B treatment in patients with Hypoplastic Left Heart Syndrome (HLHS). The data showed 100% 5-year survival and transplant-free rates, outperforming historical data. The findings support the potential of Lomecel-B as an adjunct therapy to improve outcomes for HLHS patients.

GlobeNewswire Inc.
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

Annovis Bio, a late-stage clinical drug platform company, announced that its Founder, President, and CEO, Maria L. Maccecchini, Ph.D., will participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference, including a company presentation and a panel discussion on non-amyloid approaches in Alzheimer's disease.

GlobeNewswire Inc.

Featured Companies: ANVS AVXL
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)

Longeveron announced positive results from its Phase 2a CLEAR MIND clinical trial of Lomecel-B in mild Alzheimer's disease, showing improvements in cognitive function, quality of life, and brain volume.

GlobeNewswire Inc.
Longeveron® Announces U.S. FDA Grants Fast Track - GlobeNewswire

Longeveron Inc. announced that the U.S. FDA has granted Fast Track designation to its investigational cellular therapy Lomecel-B™ for the treatment of mild Alzheimer's Disease. This designation will expedite the clinical development and regulatory review of Lomecel-B™ for this indication.

GlobeNewswire Inc.
Why WD-40 Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - Benzinga

WD-40 Company reported stronger-than-expected Q3 results, leading to a 12.5% jump in its stock price in pre-market trading. Several other stocks also saw significant price movements in the pre-market session.

Benzinga

Featured Companies: ASNS CING CTM IVP LUCY LVWR NEGG PSMT SPRC WDFC YGMZ

Dividend data last updated 06/07/2025 15:41:23 UTC